Report: World Market for Addiction Disorders, 2009 - 2016, The Future Therapies for Substance Dependence and Impulse Control TOC

Market Overview for Addiction Disorders
Market Forecasts by Therapeutic Area
- Alcohol Addiction
- Narcotic Addiction
- Tobacco Addiction

Alcohol Addiction
- Acamprosate (Campral) - Merck Serono/Forest Laboratories
- Disulfiram (Antabuse) - Alpharma
- Naltrexone Hydrochloride
- Alkermes - Reformulated Naltrexone (Vivitrol)
Pipeline Focus for Alcohol Addiction - Biotie Therapies Corp
- Nalmefene
- Naltrexone Depot
Alcohol Addiction - Market Insights and Future Considerations

Global Narcotics - Usage Statistics
Narcotic Addiction - The Scale of the Problem
Pharmacotherapies for Narcotic Addiction - Market Evaluation
Opioid Addiction Pharmacotherapies
- Drug Substitute Therapies
- Subutex/Suboxone (Buprenorphine) - Schering-Plough/Reckitt Benckiser
- Suboxone Reformulation
- Methadone
Drugs to Control Opioid Withdrawal Symptoms
- BritLofex (Lofexidine); Opizone (Naltrexone) - Britannia Pharma/STADA
- Naltrexone
- Nalorex - Bristol-Myers Squibb
- Opizone - Britannia
Therapeutic Switching in Addiction Markets
Outlook for Pharmacotherapeutic Markets Related to Alcohol and Narcotic Abuse

Addiction Disorders - Research and Development Overview
Pipeline Addiction Pharmacotherapies
Alcohol Dependence
Cocaine Dependence
Novel Late-Stage Candidates
- Celtic Pharmaceuticals
- Synosia Therapeutics/Roche
- Cannabis Dependence
- Immunotherapy Focus - InterveXion Therapeutics
Opioid Dependence
- Late-Stage Development Products for Opioid Dependence
Impulse Control Disorders
Pipeline Focus - Gambling Addiction
Tobacco/Nicotine Dependence
Pipeline Focus on Immunotherapies for Tobacco Dependence
- Nabi Biopharmaceuticals - NicVAX
- Celtic Pharmaceuticals - TA-NIC
Smoking Cessation - A Transforming Market

Table 1.1: Neurotransmitter Systems Associated with Addiction
Table 1.2: Drugs of Abuse and their Associations with Neurotransmitter Systems
Table 1.3: Estimated Prevalence of Substance Misuse in Europe, 2009 (000' users)
Table 1.4: Estimated Incidence for Addiction Disorders in North America, Europe and Japan, 2009 (incidence in 000s)
Table 2.1: Market Synopsis for Addiction Disorders: Current data
Table 2.2: Estimated Global Sales (US$) and Annual Growth (%) of Key Drugs to Treat Addictions, 2008-2016
Table 3.1: Physiological Consequences of the Disulfiram-Alcohol Reaction
Table 5.1: Estimated Sales (US$) and Annual Growth (%) of Smoking Cessation Therapies, 2008-2016
Table 6.1: Drugs in Development/Trials for Alcohol Dependence, 2009
Table 6.2: Drugs in Development/Trials for Cocaine Dependence, 2009
Table 6.3: Drugs in Development/Trials for Cannabis Dependence, 2009
Table 6.4: Drugs in Development/Trials for Ampetamine and Phencyclidine Dependencies, 2009
Table 6.5: Drugs in Development/Trials for Opioid Dependence, 2009
Table 6.6: Drugs in Development/Trials for Impulse Control Disorders, 2009
Table 6.7: Drugs in Development/Trials for Tobacco Addiction, 2009
Table 7.1: Estimated Global Drug Market (US$m) and Growth Rate (%) for Addiction Pharmacotherapies, 2008-2016
Table 7.2: Therapy Area Forecasts for the World Addiction Disorders Market, 2016 and 2025

List of Figures

Figure 1.1: Estimated Prevalence of Substance Misuse in United States, 2009
Figure 1.2: stimated Prevalence of Substance Misuse in Canada, 2009
Figure 1.3: Estimated Prevalence of Substance Misuse in Europe, 2009
Figure 1.4: Estimated Prevalence of Substance Misuse in Japan, 2009
Figure 2.1: Estimated Sales (US$) of Addiction Drugs Segmented by Therapeutic Area, 2008-2016
Figure 2.2: Estimated Global Sales (US$) of Leading Addiction Drugs by Therapy Area, 2009 & 2016
Figure 7.1: Comparative Analysis of Leading Addiction Pharmacotherapies, 2008-2016 (US$m)
Figure 7.2: Key Addiction Disorder Pharmacotherapy Prospects, 2009

World Market for Addiction Disorders, 2009 - 2016, The Future Therapies for Substance Dependence and Impulse Control